Ovid signs license deal with AstraZeneca to expand epilepsy drug pipeline
Ovid Therapeutics has signed a license agreement with AstraZeneca for a library of early-stage small molecules that target the KCC2 transporter.
Ovid Therapeutics has signed a license agreement with AstraZeneca for a library of early-stage small molecules that target the KCC2 transporter.
Ascletis Pharma is expanding the production of ritonavir oral tablets as well as the oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 virus amid the recent surge in Covid-19 cases.
Under the deal, AstraZeneca will manage the development and marketing of the antisense therapy globally.
BSF Enterprise has signed a conditional agreement to acquire 3D Bio-Tissues (3DBT) in a deal worth $3.34m (£2.5m).
Ambys Medicines has secured $47m Series A financing extension for the continued expansion of its production capabilities of liver cell therapy.
Alpine Immune Sciences and Horizon Therapeutics have signed an exclusive licence and collaboration agreement to develop protein-based therapies to treat autoimmune and inflammatory diseases.
Bristol Myers Squibb has signed a license, development, and commercialisation agreement with clinical-stage biopharmaceutical firm Immatics for the latter's TCR Bispecific candidate for solid tumours, IMA401.
Canadian biopharmaceutical firm Arbutus Biopharma has identified many molecules that can inhibit the SARS-CoV-2 nsp5 main protease (Mpro), achieving its first milestone under Covid-19 discovery research and license deal.
Quell Therapeutics has raised $156m funding through an oversubscribed Series B funding round to advance its multi-modular engineered T regulatory (Treg) cell therapy pipeline and platform.
Baidu, an AI company with internet foundation, has agreed to integrate its messenger ribonucleic acid (mRNA) design optimisation platform LinearDesign, into biopharmaceutical company Sanofi's product design pipeline.